Teachers Advisors LLC increased its holdings in La Jolla Pharmaceutical Company (NASDAQ:LJPC) by 21.5% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 30,859 shares of the biopharmaceutical company’s stock after purchasing an additional 5,469 shares during the quarter. Teachers Advisors LLC owned 0.14% of La Jolla Pharmaceutical worth $919,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Legal & General Group Plc raised its holdings in La Jolla Pharmaceutical by 11.6% in the 2nd quarter. Legal & General Group Plc now owns 4,456 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 462 shares during the period. SG Americas Securities LLC acquired a new position in La Jolla Pharmaceutical in the 1st quarter worth about $195,000. American International Group Inc. raised its holdings in La Jolla Pharmaceutical by 7.1% in the 1st quarter. American International Group Inc. now owns 8,571 shares of the biopharmaceutical company’s stock worth $256,000 after purchasing an additional 568 shares during the period. State Board of Administration of Florida Retirement System acquired a new position in La Jolla Pharmaceutical in the 1st quarter worth about $271,000. Finally, State of Wisconsin Investment Board acquired a new position in La Jolla Pharmaceutical in the 2nd quarter worth about $387,000.

A number of equities analysts have commented on the company. Jefferies Group LLC reissued a “buy” rating and set a $40.00 target price on shares of La Jolla Pharmaceutical in a report on Tuesday, October 3rd. Zacks Investment Research cut La Jolla Pharmaceutical from a “buy” rating to a “hold” rating in a report on Tuesday, July 18th. BidaskClub raised La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a report on Wednesday, August 9th. Cowen and Company reissued a “buy” rating and set a $55.00 target price on shares of La Jolla Pharmaceutical in a report on Friday, October 27th. Finally, Chardan Capital reissued a “buy” rating and set a $85.00 target price on shares of La Jolla Pharmaceutical in a report on Tuesday, August 8th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $52.00.

Shares of La Jolla Pharmaceutical Company (NASDAQ:LJPC) opened at $35.05 on Friday.

La Jolla Pharmaceutical (NASDAQ:LJPC) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported ($1.19) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.24) by $0.05. analysts forecast that La Jolla Pharmaceutical Company will post -4.94 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This article was published by Watch List News and is the property of of Watch List News. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://www.watchlistnews.com/teachers-advisors-llc-has-919000-position-in-la-jolla-pharmaceutical-company-ljpc/1677357.html.

About La Jolla Pharmaceutical

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).

Want to see what other hedge funds are holding LJPC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for La Jolla Pharmaceutical Company (NASDAQ:LJPC).

Institutional Ownership by Quarter for La Jolla Pharmaceutical (NASDAQ:LJPC)

Receive News & Ratings for La Jolla Pharmaceutical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical Company and related companies with Analyst Ratings Network's FREE daily email newsletter.